Teva Pharmaceutical Industries has made an unsolicited takeover offer to buy rival Mylan Pharmaceuticals for US$40 billion.
Valeant Pharmaceuticals International has completed the previously announced acquisition of Salix Pharmaceuticals.
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about US$3.2 billion in a move to strengthen its position on central nervous system condition treatments.
Personalized medicine is coming to 22 B.C. pharmacies selected from across the province to participate in the first-of-its-kind study, Genomics for Precision Drug Therapy in the Community Pharmacy.
A national pharmacare program wouldn’t break the bank and should in fact save taxpayers billions of dollars, a new analysis suggests.
Canada’s Valeant Pharmaceuticals International has raised its bid to acquire Salix Pharmaceuticals for about US$11.1 billion ($14.2 billion).
Dublin-based Endo International has made an unsolicited bid to acquire Salix Pharmaceuticals for about US$11 billion.
AbbVie, which terminated its deal to purchase Shire last year, has agreed to acquire Pharmacyclics for US$21 billion.
The current structure of most Canadian prior authorization (PA) programs is broken and needs to be fixed because traditional PA hasn’t changed in decades.
After failing to buy Allergan, Canada's Valeant Pharmaceuticals International has agreed to purchase Salix Pharmaceuticals for US$14.5 billion.